한글목차

세계의 내시경 점막하 박리술(ESD) 시장 규모는 예측 기간 동안 연평균 복합 성장률(CAGR) 8.4%로 확대되어, 2025년 5억 달러에서 2030년까지 7억 5,000만 달러에 이를 것으로 예측됩니다.

내시경 점막하 박리술(ESD) 도구의 기술적 진보는 이 절차의 임상적 유용성과 안전성을 크게 향상시켜 시장 성장을 견인하고 있습니다. 주입과 절단 기능을 모두 갖춘 하이브리드 나이프와 같은 기술 혁신은 박리 과정을 간소화하고 치료 시간을 단축합니다. 또한, 견인 어시스트 시스템은 시각화 및 점막 하층에 대한 접근성을 개선하여 복잡한 박리를 더욱 관리하기 쉽습니다.

고해상도 및 협대역 영상(NBI) 내시경은 병변의 검출과 단단의 평가를 더욱 향상시켜, 그 결과 수술의 정확성이 향상되고 환자 결과가 개선되었습니다. Olympus와 Fujifilm과 같은 기업은 에너지 공급 시스템, 인체공학 기반 내시경 설계, AI 기반 시각화 지원 기능을 통합한 플랫폼별 혁신에 많은 투자를 하고 있습니다.

이러한 개발은 기존 ESD와 관련된 기술적 장벽을 줄여 비학술 영역과 지역 건강 관리에서 광범위한 도입을 가능하게 하고 있습니다. 이러한 도구가 보다 직관적이고 표준화됨에 따라 새로운 의료 종사자의 학습 과정이 촉진되고, 궁극적으로 ESD가 더 친숙해지고 세계 조기 위장관 종양 관리에 선호됩니다.

내시경 점막하 박리술(ESD) 시장은 제품 유형별로 위 카메라 및 내시경, 칼, 주입제, 조직 리트랙터, 파지 클립 및 기타 제품으로 분류됩니다. 2024년에는 위 카메라 및 내시경 부문이 세계 ESD 시장에서 가장 큰 점유율을 차지했습니다.

최근의 고화질(HD) 및 4K 초고화질(UHD) 이미징 기술의 진보는 탁월한 광학 선명도와 상세한 시각화를 제공함으로써 ESD 처리를 변화시켰습니다. 협대역 이미징(NBI), 확대 내시경, 4K 스코프 등의 기능은 병변의 검출, 단단의 묘화, 전체적인 수술 정밀도를 대폭 향상시킵니다. 이러한 영상 진단의 강화는 진단 실수의 가능성을 감소시키고, 보다 정확한 박리를 가능하게 하고, 궁극적으로 환자 결과의 개선으로 이어집니다. 그 결과 위 카메라 및 내시경은 이러한 진보에 있어서 중요한 역할을 담당하고 있으며, 수술의 성공에 필수적인 공헌을 하고 있기 때문에 ESD 분야 시장 점유율을 독점하고 있습니다.

적응증별로 ESD 시장은 위암, 대장암, 식도암의 3가지로 분류됩니다. 2024년에는 위암이 ESD 시장의 최대 점유율을 차지했습니다. 강력한 임상 증거는 ESD가 점막 및 표재성 점막 하층 위 종양 치료의 최적표준임을 뒷받침합니다. ESD는 특히 전통적인 수술에 비해 높은 대량 절제율, 최소한의 국소 재발 및 우수한 장기 온존을 달성하는 것으로 장기 연구에 의해 나타났습니다. 이러한 성적은 대수술이 없는 근치적 접근이 요구되는 조기 위암에서 특히 중요합니다. 그 결과 위암 분야는 위 병변의 관리에 있어서 강력한 임상적 검증과 높은 수기량에 견인되어 ESD 시장을 선도하고 있습니다.

아시아태평양은 예측 기간 동안 ESD 시장에서 가장 큰 점유율을 차지할 것으로 예측됩니다. 일본과 한국에서는 정부가 자금을 제공하는 검진 프로그램이 내시경 검사에 의한 위 및 대장 병변의 조기 발견을 적극 추진하고 있으며, ESD의 수량이 대폭 증가하고 있습니다. 또한 이 지역은 환자의 케어와 안전성을 높이기 위해 첨단 의료 기술을 채택하는 최전선에 있습니다.

이 보고서는 세계의 내시경 점막하 박리술(ESD) 시장에 대해 조사했으며, 제품별, 적응증별, 최종 사용자별, 지역별 동향 및 시장 진출기업 프로파일 등을 정리했습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 중요 인사이트

제5장 시장 개요

• 소개
• 시장 역학
• 업계 동향
• 규제 분석
• 시장 생태계
• 밸류체인 분석
• Porter's Five Forces 분석
• 가격 분석
• 특허 분석
• 공급망 분석
• 2025년 주요 컨퍼런스 및 이벤트
• 주요 이해관계자와 구매 기준
• 고객사업에 영향을 주는 동향/혼란
• 무역 분석
• 기술 분석
• 내시경 점막하 박리술 시장 : 인접 시장
• 사례 연구 분석
• AI/생성형 AI가 내시경 점막하 박리술 시장에 미치는 영향
• 2025년 미국 관세가 내시경 점막하 박리술 시장에 미치는 영향
• 투자 및 자금조달 시나리오

제6장 내시경 점막하 박리술 시장(제품별)

• 소개
• 위 카메라 및 대장 카메라
• 칼
• 주사제
• 조직 리트랙터
• 그래스퍼 및 클립
• 기타

제7장 내시경 점막하 박리술 시장(적응증별)

• 소개
• 위암
• 대장암
• 식도암

제8장 내시경 점막하 박리술 시장(최종 사용자별)

• 소개
• 병원
• 전문 클리닉
• 외래수술센터(ASC)
• 기타

제9장 내시경 점막하 박리술 시장(지역별)

• 소개
• 아시아태평양
  • 아시아태평양의 거시 경제 전망
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 기타
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시 경제 전망
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 라틴아메리카
  • 구매력과 헬스케어 부담 능력의 향상이 시장 성장을 뒷받침
  • 라틴아메리카의 거시 경제 전망
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카
  • 헬스케어 인프라 진보에 의해 병원 설비나 의료기기 수요가 증가
  • 중동 및 아프리카의 거시경제 전망
• GCC 국가
  • 헬스케어 인프라에 대한 투자 증가와 의료 관광 확대가 시장 성장을 가속
  • GCC 국가의 거시 경제 전망

제10장 경쟁 구도

• 개요
• 주요 진입기업의 전략 및 강점
• 수익 분석
• 시장 점유율 분석
• 기업 평가 매트릭스: 주요 진입기업, 2024년
• 기업 평가 매트릭스: 스타트업 및 중소기업, 2024년
• 기업 평가 및 재무지표
• 브랜드 및 제품 비교
• 경쟁 시나리오

제11장 기업 프로파일

• 주요 진출기업
  • OLYMPUS CORPORATION
  • MEDTRONIC
  • FUJIFILM HOLDINGS CORPORATION
  • BOSTON SCIENTIFIC CORPORATION
  • SUMITOMO BAKELITE CO., LTD.
  • CREO MEDICAL GROUP PLC
  • HOYA CORPORATION
  • CONMED CORPORATION
  • STERIS
  • MTW ENDOSKOPIE MANUFAKTUR
  • OVESCO ENDOSCOPY AG
  • ZEON MEDICAL INC.
  • MICRO-TECH ENDOSCOPY
  • KARL STORZ SE & CO. KG
  • COOK MEDICAL
• 기타 기업
  • LEO MEDICAL CO., LTD.
  • ERBE ELEKTROMEDIZIN GMBH
  • TAEWOONG MEDICAL CO., LTD.
  • DCC HEALTHCARE
  • KOSSEN CO., LTD.
  • INNOVAMEDICA SPA
  • JIANGSU VEDKANG MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.
  • HANGZHOU AGS MEDICAL TECHNOLOGICAL CO., LTD.
  • BEIJING ZKSK TECHNOLOGY CO., LTD.
  • UPEX-MED CO., LTD.

제12장 부록

영문목차

The endoscopic submucosal dissection market is projected to reach USD 0.75 billion by 2030 from USD 0.50 billion in 2025, at a CAGR of 8.4% during the forecast period.

Technological advancements in endoscopic submucosal dissection (ESD) tools are significantly enhancing the procedure's clinical utility and safety, which, in turn, is driving market growth. Innovations such as hybrid knives that combine both injection and cutting capabilities have streamlined the dissection process and reduced procedural time. Additionally, traction-assisted systems have improved visualization and access to submucosal layers, making complex dissections more manageable.

High-definition and narrow-band imaging (NBI) endoscopes have further enhanced the detection of lesions and assessment of margins, resulting in increased procedural accuracy and better patient outcomes. Companies like Olympus and Fujifilm are heavily investing in platform-specific innovations, integrating energy delivery systems, ergonomic endoscope designs, and AI-based visualization aids.

These developments are reducing the technical barriers traditionally associated with ESD, enabling broader adoption in non-academic and community healthcare settings. As these tools become more intuitive and standardized, they are facilitating the learning process for new practitioners, ultimately making ESD more accessible and preferred for the management of early-stage gastrointestinal tumors worldwide.

By product, the gastroscopes & endoscopes segment accounted for the largest share of the market in 2024.

The market for endoscopic submucosal dissection (ESD) is categorized by product type into gastroscopes & endoscopes, knives, injection agents, tissue retractors, grasping clips, and other products. In 2024, the segment for gastroscopes & endoscopes held the largest share of the global ESD market.

Recent advancements in high-definition (HD) and 4K ultra-high-definition (UHD) imaging technologies have transformed ESD procedures by providing superior optical clarity and detailed visualization. Features such as narrow-band imaging (NBI), magnification endoscopy, and 4K scopes significantly enhance the detection of lesions, delineation of margins, and overall procedural accuracy. These imaging enhancements reduce the likelihood of diagnostic errors and allow for more precise dissection, ultimately leading to improved patient outcomes. Consequently, gastroscopes & endoscopes play a vital role in these advancements, which is why they dominate the market share in the ESD sector, driven by their essential contribution to the success of these procedures.

Based on indications, the stomach cancer segment dominated the ESD market in 2024.

Based on indications, the ESD market is divided into three categories: stomach cancer, colon cancer, and esophageal cancer. In 2024, stomach cancer accounted for the largest share of the ESD market. Strong clinical evidence supports ESD as the gold standard for treating mucosal and superficial submucosal gastric tumors. Long-term studies have shown that ESD achieves high rates of en bloc resection, minimal local recurrence, and excellent organ preservation, especially when compared to traditional surgery. These outcomes are particularly significant for early-stage stomach cancers, where a curative approach without major surgery is preferred. Consequently, the stomach cancer segment leads the ESD market, driven by strong clinical validation and high procedural volumes in the management of gastric lesions.

Based on region, the Asia Pacific held the largest market share in 2024.

The Asia Pacific region is projected to hold the largest share of the ESD market during the forecast period. Government-funded screening programs in Japan and South Korea are actively promoting the early detection of gastric and colorectal lesions through endoscopy, which has significantly increased ESD volumes. This region has also been at the forefront of adopting advanced medical technology to enhance patient care and safety.

A breakdown of the primary participants (supply side) for the endoscopic submucosal dissection market referred to in this report is provided below:

• By Company Type: Tier 1 (34%), Tier 2 (38%), and Tier 3 (28%)
• By Designation: C-level Executives (26%), Directors (35%), and Others (39%)
• By Region: North America (17%), Europe (39%), Asia Pacific (28%), Latin America (8%), Middle East & Africa (3%), and GCC Countries (5%)

Prominent players in the endoscopic submucosal dissection market are Olympus Corporation (Japan), FUJIFILM Holdings Corporation (Japan), Medtronic (Ireland), Boston Scientific Corporation (US), and Sumitomo Bakelite Co., Ltd. (Japan).

Research Coverage

The report assesses the endoscopic submucosal dissection market, estimating its size and future growth potential across various segments, including products, indications, end users, and regions. Additionally, the report features a competitive analysis of key players in the market, along with company profiles, product offerings, recent developments, and essential market strategies.

Reasons to Buy the Report

The report will provide valuable data on revenue estimates for the overall endoscopic submucosal dissection market and its subsegments, benefiting both market leaders and new entrants. It will help stakeholders understand the competitive landscape, enabling them to better position their businesses and develop effective go-to-market strategies. Additionally, the report will give stakeholders insights into market trends, including key drivers, challenges, restraints, and opportunities.

This report provides insights into the following points:

• Analysis of key drivers (increasing use of endoscopy in detection and treatment procedures and rising prevalence of cancer), restraints (dearth of skilled professionals and high overhead cost of ESD procedures with limited reimbursements), opportunities (growing demand for minimally invasive procedures, growing investments in R&D of endoscopy technology, and expected increase in adoption of and preference for ESD procedures in developing countries), and challenges (higher rate of complications and risk of post-operative infections).
• Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global ESD market.
• Market Development: Thorough knowledge and analysis of the profitable rising markets by product, indication, end user, and region.
• Market Diversification: Comprehensive information about newly launched products and services, expanding markets, current advancements, and investments in the global ESD market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global ESD market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS COVERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
• 1.4 YEARS CONSIDERED
• 1.5 CURRENCY USED
• 1.6 STAKEHOLDERS
• 1.7 LIMITATIONS
• 1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 METHODOLOGY-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET OVERVIEW
• 4.2 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT AND COUNTRY
• 4.3 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: GEOGRAPHIC MIX
• 4.4 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION
• 4.5 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing use of endoscopy in detection and treatment procedures
    • 5.2.1.2 Rising prevalence of cancer
    • 5.2.1.3 Growing geriatric population
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Dearth of skilled professionals
    • 5.2.2.2 High overhead cost of ESD procedures with limited reimbursements
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing demand for minimally invasive procedures
    • 5.2.3.2 Expected increase in adoption of and preference for ESD procedures in developing countries
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Higher rate of complications
    • 5.2.4.2 Risk of post-operative infection
• 5.3 INDUSTRY TRENDS
  • 5.3.1 ADVANCES IN TRACTION METHODS FOR ENDOSCOPIC SUBMUCOSAL DISSECTION
  • 5.3.2 ROBOT-ASSISTED ENDOSCOPIC SUBMUCOSAL DISSECTION
• 5.4 REGULATORY ANALYSIS
  • 5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.4.2 REGULATORY LANDSCAPE
    • 5.4.2.1 North America
      • 5.4.2.1.1 US
      • 5.4.2.1.2 Canada
    • 5.4.2.2 Europe
      • 5.4.2.2.1 Germany
      • 5.4.2.2.2 France
      • 5.4.2.2.3 UK
      • 5.4.2.2.4 Italy
• 5.5 MARKET ECOSYSTEM
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
    • 5.7.1.1 High capital requirement
    • 5.7.1.2 High preference for products from well-established brands
  • 5.7.2 THREAT OF SUBSTITUTES
    • 5.7.2.1 Presence of substitute therapies for endoscopic submucosal dissection
  • 5.7.3 BARGAINING POWER OF SUPPLIERS
    • 5.7.3.1 Presence of several raw material suppliers
    • 5.7.3.2 Supplier switching cost
  • 5.7.4 BARGAINING POWER OF BUYERS
    • 5.7.4.1 Limited number of companies offering premium products at global level
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
    • 5.7.5.1 Increasing demand for high-quality and innovative products
    • 5.7.5.2 Lucrative growth potential in emerging markets
• 5.8 PRICING ANALYSIS
  • 5.8.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT, 2024
  • 5.8.2 AVERAGE SELLING PRICE TREND OF KNIVES, BY REGION, 2022-2024 (USD)
• 5.9 PATENT ANALYSIS
• 5.10 SUPPLY CHAIN ANALYSIS
• 5.11 KEY CONFERENCES AND EVENTS DURING 2025-2025
• 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 TRENDS/DISRUPTIONS AFFECTING CUSTOMER BUSINESS
  • 5.13.1 TRENDS/DISRUPTION IMPACTING CUSTOMER'S BUSINESS
• 5.14 TRADE ANALYSIS
  • 5.14.1 IMPORT DATA
  • 5.14.2 EXPORT DATA
• 5.15 TECHNOLOGY ANALYSIS
  • 5.15.1 KEY TECHNOLOGIES
    • 5.15.1.1 Endoscopic electrosurgical knives
    • 5.15.1.2 High-definition endoscopes
  • 5.15.2 COMPLEMENTARY TECHNOLOGIES
    • 5.15.2.1 Narrow band imaging/i-scan/FICE
    • 5.15.2.2 Optical coherence tomography (OCT)
  • 5.15.3 ADJACENT TECHNOLOGIES
    • 5.15.3.1 Endoscopic mucosal resection
    • 5.15.3.2 Full-thickness resection devices
• 5.16 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: ADJACENT MARKET
• 5.17 CASE STUDY ANALYSIS
  • 5.17.1 ROBOTIC-ASSISTED ESD FOR ESOPHAGEAL TUMORS
  • 5.17.2 COST-EFFECTIVE ESD DEVICES FOR STOMACH CANCER
  • 5.17.3 PRECISION ESD FOR COLORECTAL CANCER LESIONS
• 5.18 IMPACT OF AI/GEN AI ON ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
  • 5.18.1 MARKET POTENTIAL OF AI IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
  • 5.18.2 AI USE CASES
  • 5.18.3 KEY COMPANIES IMPLEMENTING AI
  • 5.18.4 FUTURE OF GENERATIVE AI IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
• 5.19 IMPACT OF 2025 US TARIFF ON ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
  • 5.19.1 KEY TARIFF RATES
  • 5.19.2 PRICE IMPACT ANALYSIS
  • 5.19.3 IMPACT ON END-USE INDUSTRIES
• 5.20 INVESTMENT & FUNDING SCENARIO

6 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 GASTROSCOPES & COLONOSCOPES
  • 6.2.1 RISE IN COLON CANCER INCIDENCE TO DRIVE GROWTH
• 6.3 KNIVES
  • 6.3.1 IMPROVED EFFICACY, SAFETY, AND COST-EFFECTIVENESS OF KNIVES TO DRIVE MARKET GROWTH
• 6.4 INJECTION AGENTS
  • 6.4.1 NEED FOR LOW-COST INJECTION AGENTS TO BOOST GROWTH
• 6.5 TISSUE RETRACTORS
  • 6.5.1 RISING NUMBER OF SURGICAL PROCEDURES TO AID ADOPTION
• 6.6 GRASPERS/CLIPS
  • 6.6.1 PATIENT SAFETY AND HIGH PRECISION OFFERED BY GRASPERS TO DRIVE DEMAND
• 6.7 OTHER PRODUCTS

7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION

• 7.1 INTRODUCTION
• 7.2 STOMACH CANCER
  • 7.2.1 SIGNIFICANT PROPORTION OF CANCER DEATHS TO DRIVE SEGMENT
• 7.3 COLON CANCER
  • 7.3.1 INTEREST BY MEDICAL DEVICE MANUFACTURERS, CLINICAL INVESTIGATORS, AND PRACTICING CLINICIANS TO DRIVE MARKET
• 7.4 ESOPHAGEAL CANCER
  • 7.4.1 GROWING PREVALENCE OF ESOPHAGEAL CANCER TO FUEL GROWTH

8 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS
  • 8.2.1 GROWING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES AND ESD PROCEDURES TO SUPPORT GROWTH
• 8.3 SPECIALTY CLINICS
  • 8.3.1 TRANSITION FROM HOSPITAL-BASED PROCEDURES TO CLINIC-BASED PROCEDURES TO BOOST GROWTH
• 8.4 AMBULATORY SURGICAL CENTERS
  • 8.4.1 GROWTH IN SEGMENT DRIVEN BY INCREASING NUMBER OF OUTPATIENT VISITS
• 8.5 OTHER END USERS

9 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 ASIA PACIFIC
  • 9.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.2.2 JAPAN
    • 9.2.2.1 Supportive medical device reimbursement policies to drive market growth
  • 9.2.3 CHINA
    • 9.2.3.1 Large patient population and strong need for healthcare infrastructure improvements to boost market growth
  • 9.2.4 INDIA
    • 9.2.4.1 Favorable government initiatives for healthcare infrastructure improvements to support market growth
  • 9.2.5 SOUTH KOREA
    • 9.2.5.1 Rapidly aging population and high incidence of gastrointestinal diseases to aid market growth
  • 9.2.6 AUSTRALIA
    • 9.2.6.1 High incidence of cancer to propel market growth
  • 9.2.7 REST OF ASIA PACIFIC
• 9.3 NORTH AMERICA
  • 9.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.3.2 US
    • 9.3.2.1 Largest market for endoscopic submucosal dissection products
  • 9.3.3 CANADA
    • 9.3.3.1 Slower healthcare development over past decade to restrain growth
• 9.4 EUROPE
  • 9.4.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.4.2 GERMANY
    • 9.4.2.1 Germany to account for largest share of European market
  • 9.4.3 FRANCE
    • 9.4.3.1 High-quality healthcare system offering coverage to all citizens to support market growth
  • 9.4.4 UK
    • 9.4.4.1 Investments by hospitals to purchase new and advanced endoscopic submucosal dissection equipment to propel market
  • 9.4.5 ITALY
    • 9.4.5.1 Receptivity of government toward high-quality and technologically advanced equipment to foster growth
  • 9.4.6 SPAIN
    • 9.4.6.1 Rising prevalence of cancer to drive market growth
  • 9.4.7 REST OF EUROPE
• 9.5 LATIN AMERICA
  • 9.5.1 INCREASING PURCHASING POWER AND HEALTHCARE AFFORDABILITY TO FAVOR MARKET GROWTH
  • 9.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.3 BRAZIL
    • 9.5.3.1 Increase in private healthcare investments and rise in medical tourism to aid market growth
  • 9.5.4 MEXICO
    • 9.5.4.1 Increased government investment in healthcare infrastructure and technological advancements to aid market growth
  • 9.5.5 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 ADVANCEMENTS IN HEALTHCARE INFRASTRUCTURE TO CREATE NEED FOR HOSPITAL EQUIPMENT AND MEDICAL DEVICES
  • 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 9.7 GCC COUNTRIES
  • 9.7.1 INCREASING INVESTMENT IN HEALTHCARE INFRASTRUCTURE AND GROWING MEDICAL TOURISM TO PROPEL MARKET GROWTH
  • 9.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
• 10.3 REVENUE ANALYSIS
• 10.4 MARKET SHARE ANALYSIS
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Product footprint
    • 10.5.5.4 Indication footprint
    • 10.5.5.5 End user footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 10.6.5.1 Detailed list of key startups/SMEs
    • 10.6.5.2 Competitive benchmarking of key startups/SMEs
• 10.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 10.7.1 FINANCIAL METRICS
  • 10.7.2 COMPANY VALUATION
• 10.8 BRAND/PRODUCT COMPARISON
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 OLYMPUS CORPORATION
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Deals
      • 11.1.1.3.2 Expansions
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Right to win
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses and competitive threats
  • 11.1.2 MEDTRONIC
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 MnM view
      • 11.1.2.3.1 Right to win
      • 11.1.2.3.2 Strategic choices
      • 11.1.2.3.3 Weaknesses and competitive threats
  • 11.1.3 FUJIFILM HOLDINGS CORPORATION
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product launches & approvals
      • 11.1.3.3.2 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Right to win
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses and competitive threats
  • 11.1.4 BOSTON SCIENTIFIC CORPORATION
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 MnM view
      • 11.1.4.3.1 Right to win
      • 11.1.4.3.2 Strategic choices
      • 11.1.4.3.3 Weaknesses and competitive threats
  • 11.1.5 SUMITOMO BAKELITE CO., LTD.
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 MnM view
      • 11.1.5.3.1 Right to win
      • 11.1.5.3.2 Strategic choices
      • 11.1.5.3.3 Weaknesses and competitive threats
  • 11.1.6 CREO MEDICAL GROUP PLC
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Deals
      • 11.1.6.3.2 Expansions
  • 11.1.7 HOYA CORPORATION
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
  • 11.1.8 CONMED CORPORATION
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
  • 11.1.9 STERIS
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Deals
  • 11.1.10 MTW ENDOSKOPIE MANUFAKTUR
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
  • 11.1.11 OVESCO ENDOSCOPY AG
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
  • 11.1.12 ZEON MEDICAL INC.
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
  • 11.1.13 MICRO-TECH ENDOSCOPY
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Product launches
  • 11.1.14 KARL STORZ SE & CO. KG
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
  • 11.1.15 COOK MEDICAL
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products offered
    • 11.1.15.3 Recent developments
      • 11.1.15.3.1 Product launches
• 11.2 OTHER COMPANIES
  • 11.2.1 LEO MEDICAL CO., LTD.
  • 11.2.2 ERBE ELEKTROMEDIZIN GMBH
  • 11.2.3 TAEWOONG MEDICAL CO., LTD.
  • 11.2.4 DCC HEALTHCARE
  • 11.2.5 KOSSEN CO., LTD.
  • 11.2.6 INNOVAMEDICA S.P.A.
  • 11.2.7 JIANGSU VEDKANG MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.
  • 11.2.8 HANGZHOU AGS MEDICAL TECHNOLOGICAL CO., LTD.
  • 11.2.9 BEIJING ZKSK TECHNOLOGY CO., LTD.
  • 11.2.10 UPEX-MED CO., LTD.

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS